I've been thinking about this for a bit. I just came back from a talk about atypical HUS and eculizumab. You can all google that if you want. Anyway, my guess is that RVX is targeting an orphan hemtalogical condition such as catastrophic anti-phospholipid antibody syndrome. There is some info that BRD issues may be associated with its development. They could be targeting any other number of rare autoimmune conditions....presumable something came out of all the tests they ran on all the blood they collected in their trials. Orphan drug companies charge high amounts for their drug as the target population is limited. I'm not sure how this would work with 208 if RVX ultimately wants it to be a chronic therapy for many. Nevertheless, any new reason to look at getting this drug on the market is positive for shareholders. Just take a look at a long term chart of Alexion to see what an orphan drug company can achieve. Bfw